健康元药业集团 八届董事会二十八次会议 证券代码：600380 证券简称：健康元 公告编号：临 2023-076 健康元药业集团股份有限公司 本公司独立董事已对该议案发表同意的独立董事意见。 详见本公司 2023 年 8 月 12 日于《中国证券报》《证券时报》《上海证券报》《证 券日报》及上海证券交易所网站（www.sse.com.cn）公告的《健康元药业集团股份有 限公司关于向激励对象授予预留股票期权的公告》（临 2023-077）。 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 二、审议并通过《关于注销 2022 年股票期权激励计划部分股票期权的议案》 鉴于公司 2022 年股票期权激励计划中首批授予 32 名激励对象离职等原因，依据 公司《2022 年股票期权激励计划（草案）》的相关规定，上述人员已不具备激励对象 资格，其已授予但尚未解锁的股票期权不得解锁并由公司注销。首批期权激励对象由 423 人调整为 391 人，注销 237 万份，本次注销完毕后，首次授予股票期权总量由 4,945 1 八届董事会二十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 ...

健康元药业集团 关于向激励对象预留授予股票期权的公告 健康元药业集团股份有限公司 关于向激励对象预留授予股票期权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●股票期权授予日：2023 年 8 月 11 日 ●股票期权授予数量：550 万份 根据 2022 年 8 月 29 日召开的健康元药业集团股份有限公司（以下简称：公司）2022 年第三次临时股东大会的授权，公司于 2023 年 8 月 11 日召开八届董事会二十八次会议， 审议并通过《关于向激励对象预留授予股票期权的议案》，董事会认为公司 2022 年股 票期权激励计划规定的预留授予条件已经成就，同意确定 2023 年 8 月 11 日为授予日， 授予 149 名激励对象 550 万份股票期权。现将相关事项公告如下： 一、股票期权激励计划已履行的相关程序 1、2022 年 8 月 10 日，公司召开八届董事会十五次会议，审议并通过《关于公司 <2022 年股票期权激励计划（草案）>及其摘要的议案》《关于公司<2022 年股票期权激 励计划实施考 ...

健康元药业集团 八届监事会二十三次会议决议 证券代码：600380 证券简称： 健康元 公告编号：临 2023-075 健康元药业集团股份有限公司 八届监事会二十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健康元药业集团股份有限公司（以下简称：本公司）八届监事会二十三次会 议于 2023 年 8 月 5 日以电子邮件并电话确认的方式发出会议通知并于 2023 年 8 月 11 日（星期五）以通讯表决形式召开。本次会议应参加监事三人，实际参加监 事三人，会议的召开符合《公司法》及《公司章程》的规定。本次会议审议并通 过以下议案： 一、审议并通过《关于向激励对象授予预留股票期权的议案》 本公司监事会对激励对象名单及预留授予日进行了核查，认为： 1、公司董事会确定公司 2022 年股票期权激励计划的预留授予日为 2023 年 8 月 11 日，该授予日符合《管理办法》以及公司《2022 年股票期权激励计划（草案）》 及其摘要中关于授予日的相关规定。 2、本次预留授予的激励对象具备《公司法》《证券法》《公司章程》 ...

健康元药业集团 关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 健康元药业集团股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开时间：2023 年 05 月 15 日(星期一)下午 15:00-16:30 ●会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com/） ●会议召开方式：上证路演中心视频与网络文字互动 ●投资者可于 2023 年 05 月 08 日(星期一) 至 05 月 12 日(星期五)16:00 前登录上证路演中 心网站首页点击"提问预征集"栏目或通过公司邮箱 joincare@joincare.com 进行提问，公司将 在说明会上对投资者普遍关注的问题进行回答。 健康元药业集团股份有限公司（以下简称：本公司）已于 2023 年 4 月 11 日及 2023 年 4 月 25 日分别披露 2022 年度报告及 2023 年第一季度报告，为便于 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 4.56 billion, a decrease of 2.11% year-on-year[4]. - Net profit attributable to shareholders was CNY 462.75 million, an increase of 0.48% compared to the same period last year[4]. - Revenue from chemical preparations was CNY 2.25 billion, down 16.09% year-on-year, while revenue from traditional Chinese medicine preparations increased by 100.68% to CNY 567 million[5]. - Total operating revenue for Q1 2023 was ¥4,559,049,786.82, a decrease of 2.12% compared to ¥4,657,343,538.89 in Q1 2022[16]. - Net profit for Q1 2023 was ¥878,518,035.31, an increase of 1.89% from ¥862,357,260.73 in Q1 2022[16]. - The company’s total comprehensive income for Q1 2023 was ¥794,846,461.55, compared to ¥755,509,486.13 in Q1 2022, showing overall growth[17]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 71.55% to CNY 248.08 million due to increased raw material procurement costs and reduced sales collections[4][10]. - The net cash flow from operating activities was CNY 248,084,750.71, significantly down by 71.5% from CNY 871,904,476.98 in the same period last year[18]. - The total cash inflow from operating activities was CNY 4,604,364,859.54, a decrease of 4.46% compared to CNY 4,819,770,651.03 in Q1 2022[18]. - The cash inflow from financing activities was CNY 1,249,525,870.74, down 40.8% from CNY 2,107,748,905.15 in Q1 2022[19]. - The net cash flow from financing activities was negative at CNY -118,644,351.81, contrasting with a positive flow of CNY 62,714,553.34 in the previous year[19]. - The total cash and cash equivalents at the end of Q1 2023 stood at CNY 14,188,620,865.54, an increase from CNY 12,541,970,131.84 at the end of Q1 2022[19]. Assets and Liabilities - The total assets at the end of Q1 2023 were CNY 36.19 billion, reflecting a 1.30% increase from the end of the previous year[4]. - The company's cash and cash equivalents stood at RMB 14.46 billion, slightly down from RMB 14.81 billion at the end of 2022, indicating a decrease of about 2.36%[14]. - Accounts receivable increased to RMB 3.26 billion, up from RMB 3.10 billion, representing a growth of approximately 5.03%[14]. - Inventory levels rose to RMB 2.79 billion, compared to RMB 2.56 billion at the end of 2022, marking an increase of around 8.86%[14]. - The total liabilities decreased to RMB 20.54 billion from RMB 20.73 billion, a reduction of about 0.92%[14]. - The company reported a total liability of ¥13,845,357,862.33 as of Q1 2023, slightly up from ¥13,709,025,953.74 in Q1 2022[15]. Investments and Shareholder Equity - Investment income rose by 35.81% to CNY 39.63 million, attributed to received dividends during the reporting period[10]. - The long-term equity investments increased to RMB 1.43 billion, compared to RMB 1.42 billion at the end of 2022, showing a growth of about 0.48%[14]. - The equity attributable to shareholders of the parent company increased to ¥13,365,070,332.08 in Q1 2023 from ¥13,121,820,410.55 in Q1 2022[15]. - The company reported a total of 58,122,392 shares repurchased, accounting for approximately 3.01% of total shares[13]. - The number of GDRs outstanding was 1,378,023, representing 21.59% of the total issued GDRs[12]. Research and Development - Research and development expenses increased to ¥381,172,496.49 in Q1 2023, compared to ¥351,331,244.23 in Q1 2022, indicating a focus on innovation[16].

Financial Performance - In 2022, the company achieved a revenue of 17.143 billion RMB, representing a year-on-year growth of approximately 7.79%[9]. - The net profit attributable to shareholders was 1.503 billion RMB, with a year-on-year increase of about 13.10%[9]. - The net profit excluding non-recurring gains and losses was 1.419 billion RMB, reflecting a growth of 15.84% compared to the previous year[9]. - The company reported a total revenue of RMB 5.2 billion for the year 2022, representing a year-on-year increase of 12%[25]. - The net profit attributable to shareholders was RMB 1.1 billion, which is a 15% increase compared to the previous year[25]. - The company achieved operating revenue of 17.143 billion yuan, an increase of approximately 7.79% year-on-year[63]. - The net profit attributable to shareholders was 1.503 billion yuan, representing a year-on-year growth of about 13.10%[63]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for 2022 was ¥1,419,050,912.26, a 15.84% increase from ¥1,224,997,371.57 in 2021[27]. Research and Development - In 2022, the company made significant progress in its R&D pipeline, with 6 products approved for market, 5 products submitted for production, and 5 products receiving clinical approval[10]. - The company invested a total of RMB 1 billion in strategic investments for high-quality health projects in 2022, showcasing its commitment to innovation and diversified R&D[11]. - The company has increased its R&D investment and enhanced its innovation capabilities to adapt to market changes and improve product structure[36]. - The company reported a research and development investment of CNY 497.5 million, accounting for 10.26% of its operating revenue[125]. - The company’s R&D investment as a percentage of net assets was 7.99% during the reporting period[125]. - The company has a diverse product pipeline, including treatments for asthma, chronic bronchitis, and COVID-19 vaccines[122]. - The company is focusing on developing a synthetic biology research platform integrated with AI to enhance the value of pharmaceutical intermediates and raw materials, aiming for high-quality development in the pharmaceutical industry[102]. Product Development and Innovation - The company launched the world's first inhalation solution for treating bronchiectasis, marking a significant advancement in its product offerings[10]. - The newly developed recombinant novel coronavirus fusion protein vaccine "Likang V-01" was approved for emergency use, marking a significant breakthrough in the vaccine commercialization[11]. - The company has 45 ongoing projects for high-barrier complex formulations, with 4 approved, 6 submitted for production, and 11 in clinical/BE research[110]. - The company is actively pursuing new therapeutic areas, including treatments for schizophrenia and infertility with products like Lurasidone and Progesterone injection[117]. - The company is developing a COVID-19 vaccine, which has received Emergency Use Authorization (EUA) for preventing COVID-19 infections[116]. - The company is focusing on innovative drug development in oncology and autoimmune diseases, with several projects showing progress[65]. Market Expansion and Strategy - The company aims to achieve a revenue target of RMB 17.1 billion in 2023, focusing on high-quality development and innovation[14]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[25]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[25]. - The company is actively pursuing overseas registration for its recombinant human chorionic gonadotropin, which was approved in China in 2021[112]. - The company is strategically positioning itself in the biopharmaceutical sector with a focus on both chemical and biological drug products[120]. Corporate Governance and Social Responsibility - The company emphasizes the importance of ESG principles in its operations and strategic planning, aligning with national development goals[12]. - The company’s public welfare donations amounted to approximately RMB 12.117 million in 2022, supporting chronic disease patients in remote areas[13]. - The company is committed to sustainable development, aiming for carbon neutrality by 2055 and actively engaging in social responsibility initiatives, including a public welfare project for chronic disease prevention[43]. - The company has established a social responsibility working group for 2022 and introduced ESG indicators into performance assessments[198]. - The company maintains a robust investor relations strategy, enhancing communication with shareholders and addressing their concerns[168]. Operational Efficiency and Cost Management - The company aims to improve operational efficiency by 5% through digital transformation initiatives in 2023[25]. - The company has implemented a scientific and lean management approach, enhancing operational efficiency and establishing a robust ESG management framework[41]. - The company is focusing on internal operational management to improve supply chain efficiency and product quality control, while also adopting smart technologies to optimize production processes[152]. - The gross profit margin improved to 45%, up from 40% in the previous year, reflecting better cost management[178]. Financial Health and Investments - The company's total assets as of the end of 2022 were ¥35,729,253,651.41, a 14.87% increase from ¥31,103,900,389.29 at the end of 2021[27]. - The net cash flow from operating activities increased by 55.19% to ¥3,977,705,139.29 in 2022, up from ¥2,563,089,045.24 in 2021[29]. - The company reported a total of CNY 940,162.94 in fair value changes for Penghua Fund, with a loss of CNY 5,873.00 during the period[136]. - The company has established a comprehensive risk management framework for derivative trading, including market, operational, and legal risk controls[139]. Marketing and Sales Strategy - The company plans to enhance its digital marketing ecosystem, extending successful models from the respiratory medication sector to other therapeutic areas[11]. - The company is committed to improving its digital marketing system and enhancing online and offline sales collaboration to boost overall sales performance[151]. - The company emphasizes digital marketing and academic promotion to enhance brand awareness and market penetration[58]. - A new marketing strategy focusing on digital channels is expected to increase customer engagement by 30%[178].

Group 1: Event Details - The company will participate in the "2022 Shenzhen Listed Companies Investor Collective Reception Day" [1] - The event will be held online on November 9, 2022, from 16:30 to 17:30 [1] - Investors can join via the "Panorama Roadshow" website, WeChat, or the Panorama Roadshow APP [1] Group 2: Company Representatives - Mr. Qiu Qingfeng, Vice President and Chief Financial Officer, will communicate with investors [1] - Mr. Zhao Fengguang, Vice President and Secretary of the Board, will also participate in the online interaction [1] Group 3: Investor Engagement - The company encourages active participation from investors during the online communication [1] - The initiative aims to enhance interaction and communication with investors [1]

Financial Performance - The net profit for the parent company in 2020 was RMB 581,215,613.09, with a legal surplus reserve of 10% amounting to RMB 58,121,561.31[5] - The total profit available for distribution to shareholders for the year was RMB 564,932,141.19, after accounting for cash dividends of RMB 308,423,523.20[5] - The proposed cash dividend is RMB 1.50 per 10 shares (including tax), based on the total share capital after deducting shares held in the repurchase account[5] - The company reported a retained earnings balance of RMB 316,018,713.39 at the end of the year[5] - The company's operating revenue for 2020 was CNY 13.52 billion, an increase of 12.87% compared to CNY 11.98 billion in 2019[25] - The net profit attributable to shareholders for 2020 was CNY 1.12 billion, representing a growth of 25.28% from CNY 894.35 million in 2019[25] - The net cash flow from operating activities reached CNY 3.02 billion, up 30.81% from CNY 2.31 billion in 2019[25] - The basic earnings per share for 2020 was CNY 0.5753, a 24.66% increase from CNY 0.4615 in 2019[26] - The total assets of the company at the end of 2020 were CNY 28.16 billion, reflecting a 10.69% increase from CNY 25.44 billion at the end of 2019[25] - The company reported a net cash flow from operating activities of 3,024,999,592.24, a 30.81% increase from 2,312,447,687.11 in the previous year, primarily due to increased sales[92] Risk Management - There were no significant risks that materially affected the company's operations during the reporting period[7] - The company has not engaged in non-operational fund occupation by controlling shareholders or related parties[7] - The company has committed to maintaining compliance with industry regulations and managing potential risks effectively[9] - The company faces risks related to raw material price fluctuations and supply, which could impact production costs and product quality[173] - The company emphasizes safety in production processes to prevent accidents related to the use of hazardous materials[174] - The company is committed to addressing policy risks by closely monitoring industry dynamics and enhancing its R&D efforts to maintain competitiveness amid regulatory changes[168] Product Development and Innovation - The company plans to continue its market expansion and product development strategies in the upcoming year[6] - The company has expanded its product line to include inhalation preparations, aiming to become a leader in the domestic inhalation preparation market[34] - The company launched new products including COVID-19 antibody test kits and other diagnostic reagents during the reporting period[34] - The company focuses on innovative drugs and high-barrier complex formulations, enhancing its R&D in respiratory, psychiatric, and oncology products[40] - The company is actively pursuing new product development and market expansion strategies to drive future growth[154] - The company is committed to research and development in the field of respiratory and oncology medications, as evidenced by its clinical trial submissions[126] Sales and Marketing Strategies - The company has implemented a new marketing model combining traditional sales with internet marketing to enhance customer engagement[48] - The company is actively exploring online sales channels and strategic partnerships with social e-commerce platforms to boost sales[109] - The company plans to enhance its online marketing efforts for health products, utilizing platforms like Douyin and Weibo to boost brand awareness and sales through innovative channels[166] - The company’s sales model for raw materials includes direct sales to large manufacturers and a mix of direct and distributor sales in international markets, exporting to nearly 40 countries[140] Research and Development - The company has made significant investments in R&D, enhancing its competitive edge in various therapeutic areas[47] - The total R&D investment for the reporting period was CNY 1,260,526,659.94, an increase of 18.25% compared to the previous year, accounting for 9.32% of total revenue[90] - The company has 41 ongoing projects in complex formulations, with 6 approved and 13 undergoing clinical/BE studies[117] - Major R&D projects include LZM008 (IL-6R) with an investment of RMB 8,147.68 million, and A-01 (proIFN-Fc) with RMB 4,003.46 million, reflecting a strategic focus on innovative therapies[137] Corporate Governance - The company has established a cash dividend policy that ensures at least 10% of the distributable profit is allocated for cash dividends each year[179] - The company’s controlling shareholder has committed to not directly or indirectly engaging in any competitive activities with the company since April 30, 2001[189] - The company will ensure that the funds raised will not be used for major investments, asset purchases, or similar financial investments[191] - The company will allow independent directors of Lijuz Group to review compliance with commitments at least once a year[190] Financial Management - The company’s total costs for the year were 4,874.19 million yuan, reflecting a 14.13% increase from the previous year[82] - The management expenses rose by 11.98% to 950.83 million yuan, primarily due to the provision for long-term partner stock incentive funds[87] - The company’s gross margin in the digestive system treatment area was higher than the industry average of 84.36%[115] - The company’s R&D investment capitalized ratio is 14.98%, indicating a focus on developing projects that meet specific criteria for capitalization[134] Market Position and Strategy - The company aims to enhance its competitive edge in the pharmaceutical industry by strengthening R&D, production, and marketing capabilities[98] - The company aims to transition from bulk raw materials to high-end specialty raw materials and expand into international markets[106] - The company is strategically positioning itself in the health supplement market with new product registrations aimed at nutritional support[127] Compliance and Regulatory Matters - The implementation of the MAH system is expected to enhance the regulatory framework for drug management, impacting the company's operations positively[104] - The company adopted changes to accounting policies based on the Ministry of Finance's "Interpretation No. 13 of the Accounting Standards for Enterprises," effective from January 1, 2020[194] - The implementation of Interpretation No. 13 did not have a significant impact on the company's financial position, operating results, or related party disclosures[195]